MedTrace Logo

Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities

NCT04220229 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2025-07-17

Study results available
· View outcomes & findings →

Summary

This phase I/II trial studies the side effects and best dose of cabozantinib when given with radiation therapy and how well it works in treating patients with sarcoma of the extremities. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving cabozantinib with radiation therapy may make the tumors smaller and reduce the amount of normal tissue that needs to be removed.

Conditions

  • Sarcoma of the Extremity
  • Stage I Soft Tissue Sarcoma of the Trunk and Extremities
  • Stage IA Soft Tissue Sarcoma of the Trunk and Extremities
  • Stage IB Soft Tissue Sarcoma of the Trunk and Extremities
  • Stage II Soft Tissue Sarcoma of the Trunk and Extremities

Interventions

DRUG

Cabozantinib S-malate

Given PO

RADIATION

Radiation Therapy

Undergo standard of care radiation therapy

Sponsors & Collaborators

Principal Investigators

  • Lee Cranmer, MD, PhD · Fred Hutch/University of Washington Cancer Consortium

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2024-04-05
Completion
2024-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04220229 on ClinicalTrials.gov